Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q2 FY25 Earnings Presentation
15 slides from Gland Pharma's earnings presentation, Nov 4, 2024
Slide 1: Gland Pharma Limited Financial Results Q2'FY25
Gland Pharma Limited Financial Results Q2’FY25 4th November 2024
Slide 2: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 3: Group Financial Highlights (1/4)
Group Financial Highlights (1/4) Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (INR Mn) (INR Mn / %) 28,075 25,821 16,077 16,678 62% 59% 13,734 14,017 14,058 8,519 8,375 8,304 62% 59% 60% Q2 FY24 Q1 FY25 Q2 FY25 6M FY24 6M FY25 Q2 FY24 Q1 FY25 Q2 FY25 6M FY24 6M FY25 EBITDA (3)
Slide 4: Gland Financial Highlights (Ex-Cenexi) (2/4)
Gland Financial Highlights (Ex-Cenexi) (2/4) Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn / %) (INR Mn) 6,586 6,109 20,793 5% 32% 19,019 32% 3,473 3,645 10,659 2,941 10,146 10,134 34% 34% 29% Q2 FY24 Q1 FY25 Q2 FY25 6M FY24 6M FY25 Q2 FY24 Q1 FY25 Q2 FY25 6M FY24 6M FY25 PBT / PAT
Slide 5: Group Financial Highlights (3/4)
Group Financial Highlights (3/4) Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 87,238 87,880 28,201 24,953 25,413 21,756 Mar'24 Sep'24 Mar'24 Sep'24 Total Cash Net Cash Net Working Capital (3) Capital Expenditure (INR Mn) (INR Mn) 24,074 1,657 1,674 20,453 Mar'24 Sep'24 6M FY
Slide 6: Group Financial Highlights (4/4)
Group Financial Highlights (4/4) Asset Turnover Ratio (1)(2) ROCE (3) / RONW (4) (%) 2.1 1.5 1.5 10% 9% 10% 7% 9% 0.6 0.6 0.5 7% Total asset turnover Fixed asset turnover 6M FY24 FY24 6M FY25 6M FY24 FY24 6M FY25 RoCE RoNW Cash Flow from Operations Cash Conversion Cycle (CCC) (5)(6) (INR Mn) (# of D
Slide 7: P&L Highlights
P&L Highlights Group P&L INR Mn Particulars Q2 FY25 Q2 FY24 YoY 6M FY25 6M FY24 YoY Q1 FY25 QoQ Revenue from operations 14,058 13,734 2% 28,075 25,821 9% 14,017 0% Other Income 596 532 12% 1,111 907 22% 514 16% Total Income 14,654 14,266 3% 29,186 26,728 9% 14,531 1% Gross Margin(1) 8,304 8,519 -3%
Slide 8: Base Business (Ex-Cenexi) Performance
Base Business (Ex-Cenexi) Performance Q2FY25 Highlights • Revenue: INR 10,659 million, driven by volume growth in key injectables and new product launches compared to Q2FY24. • Gross margin: 56%. • EBITDA: INR 3,645 million, EBITDA margins were at 34%. • R&D expenses: INR 493 million (4.6% of revenu
Slide 9: Cenexi Performance
Cenexi Performance Q2FY25 Highlights • Revenue: INR 3,399 million / Euro 37 million • Gross margin: 69% • EBITDA: INR -685 million / Euro -7.5 million Key Updates: Fontenay Site (Paris, France): • Our new high-capacity ampoule line is on track for commercial production in January 2025. This project
Slide 10: Segment wise revenue break-up
Segment wise revenue break-up
Slide 11: US Market
US Market Group Revenue Contribution US Market (Ex-Cenexi) 6M FY25: Rs. 15,175 Mn Q2 FY25: Rs. 7,547 Mn ▪ Revenue: YoY Change: 13% YoY Change: 3% Launched 4 molecules in the market, including Cetrorelix Acetate, Ephedrine Sulfate, Tranexamic Acid and Diazepam. Q2 Q2 ▪ New launches(1): FY24 54% FY25
Slide 12: Europe, Other Core Markets (Canada, Australia and New Zealand)
Europe, Other Core Markets (Canada, Australia and New Zealand) Europe Other Core Markets (Canada, Australia and New Zealand) Group Revenue Contribution Group Revenue Contribution 6M FY25: Rs. 5,025 Mn Q2 FY25: Rs. 2,459 Mn 6M FY25: Rs. 962 Mn Q2 FY25: Rs. 515 Mn YoY Change: 7% YoY Change: -1% YoY Ch
Slide 13: Rest of the World Markets
Rest of the World Markets Group Revenue Contribution Rest of the World Markets (Ex-Cenexi) ▪ The Rest of the World markets contributed 16% of our 6M FY25: Rs. 5,512 Mn Q2 FY25: Rs. 2,663 Mn YoY Change: -1% YoY Change: 0% revenue in Q2 FY25, compared to 17% in Q2 FY24. 19% 19% ▪ We registered Ziprasi
Slide 14: India (Domestic Market)
India (Domestic Market) Group Revenue Contribution India - Domestic Market (Ex-Cenexi) 6M FY25: Rs. 1,401 Mn Q2 FY25: Rs. 874 Mn ▪ The Indian market made up 8% of our revenue in Q2 YoY Change: -8% YoY Change: 0% 6% 6% FY25, compared to 9% in Q2 FY24. Q2 Q2 FY25 FY24 Gland Revenue Contribution (Ex-Ce
Slide 15: GLAND
Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District Hyder